Healthcare, Pharma & Life Sciences

MOYOM Biotech Lands Cathay Capital Funding for Global Expansion

Image
MOYOM Biotech Lands Cathay Capital Funding for Global Expansion

Shanghai – – September 28, 2026 -- MOYOM Biotech, a Chinese developer of regenerative aesthetic biomaterials, has secured a new financing round from the Cathay Consumer Co-Creation Fund, managed by Cathay Capital, to fund international expansion of its flagship CaHA-based implant brand Aphranel®.

Cathay Capital Fund Backed by L'Oréal Targets Beauty and Skin Science Innovation

The investment vehicle was jointly established by Cathay Capital, L'Oréal and the Shanghai Jing'an District Government. Cathay Capital's broader portfolio includes Moonshot AI (Kimi), autonomous driving firm Momenta, U.S. fintech Chime, digital asset platform Ledger, delivery platform Glovo and AI biotech company Owkin.

IDEAYA Biosciences Promotes Michael White to President, R&D

Image
IDEAYA Biosciences Promotes Michael White to President, R&D

South San Francisco, Calif. – September 28, 2026 -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA) promoted Dr. Michael White from Chief Scientific Officer to President, Research and Development, effective September 28, 2026.

White expands authority over IDEAYA's oncology pipeline after five years as CSO

Dr. White has served as Chief Scientific Officer at IDEAYA since 2021, overseeing research into synthetic lethality and antibody-drug conjugate (ADC) programs targeting solid tumors. The precision medicine oncology company's pipeline spans multiple indications, including uveal melanoma, pancreatic cancer, small cell lung cancer, non-small cell lung cancer, colorectal cancer and breast cancer.

AxisCare Launches AI Receptionist to Cut Home Care Call-Off Chaos

Image
AxisCare Launches AI Receptionist to Cut Home Care Call-Off Chaos

Waco, Texas – – September 28, 2026 -- AxisCare has launched Axi Assist, an AI-powered receptionist built into its home care management platform to handle caregiver call-offs and missed clock-ins around the clock, including nights, weekends, and holidays.

Axi Assist captures caregiver call-off details and triggers scheduling workflows immediately, even outside office hours.

The tool answers calls, records information, and starts rescheduling processes without waiting for a coordinator to check voicemail, addressing a recurring operational bottleneck for home care agencies that rely on on-call staff to cover gaps.

SOLA Japan Wins ¥6B AMED Grant for ALS Gene Therapy SOL-257

Tokyo – September 28, 2026 -- SOLA Biosciences Japan GK has secured a grant of approximately 6 billion yen over five years from Japan's Agency for Medical Research and Development (AMED) to advance SOL-257, a gene therapy candidate targeting the TDP-43 protein implicated in amyotrophic lateral sclerosis (ALS). The award, granted under AMED's Strengthening Program for Pharmaceutical Startup Ecosystem, was announced June 5, 2026, and positions SOLA Japan as the company's central development hub for the program.

AMED grant targets a pathology present in 97% of ALS cases

SOL-257 is designed to restore the structure and function of misfolded TDP-43, a protein that becomes mislocalized and aggregated in motor neurons in roughly 97% of ALS cases, according to SOLA. The company describes SOL-257 as a potentially first-in-class, disease-modifying gene therapy built on its proprietary JUMP70 platform.

Grünenthal, DKSH Expand Pain Drug Access to Eight Asia-Pacific Markets

Image
Grünenthal, DKSH Expand Pain Drug Access to Eight Asia-Pacific Markets

Aachen, Germany – September 28, 2026 -- Grünenthal and DKSH Business Unit Healthcare have signed a new commercialisation agreement to bring four pain medicines, Qutenza, Vimovo, Palexia and Zomig, to eight Asia-Pacific markets: Hong Kong, Indonesia, Malaysia, the Philippines, Singapore, Taiwan, Thailand and Vietnam.

DKSH takes over local regulatory filings and distribution across eight markets

Under the agreement, DKSH will seek local marketing authorisations and handle marketing, medical affairs, market access, sales and distribution for the four medicines in each of the eight markets, pending regulatory approval. Grünenthal will retain manufacturing responsibility through its global production network. Each market could gain access to up to four new medicines depending on approval timelines.

Akeso Enrolls First Patient in Global Phase III Gastric Cancer Trial

Hong Kong – September 28, 2026 -- Akeso, Inc. (9926.HK) has enrolled the first patient in COMPASSION-37, a global Phase III head-to-head trial testing its bispecific antibody cadonilimab against nivolumab as first-line treatment for HER2-negative advanced gastric and gastroesophageal junction (G/GEJ) adenocarcinoma.

Trial pits cadonilimab plus chemotherapy against nivolumab-based standard of care

The multicenter study compares cadonilimab combined with chemotherapy to chemotherapy with or without nivolumab in previously untreated, unresectable or metastatic G/GEJ patients. It is co-led by Dr. Yelena Y. Janjigian of Memorial Sloan Kettering Cancer Center, Professor Markus Möhler of Johannes Gutenberg University Mainz, and Professors Jiafu Ji and Lin Shen of Peking University Cancer Hospital. Janjigian, Möhler and Shen were investigators on the earlier CheckMate 649 trial, which established nivolumab plus chemotherapy as a global first-line standard.

Cuvo Health Report: Only 14 States Ease Telehealth Licensing

Image
Cuvo Health Report: Only 14 States Ease Telehealth Licensing

Wilmington, Del. – September 28, 2026 -- A new 51-jurisdiction dataset from Cuvo Health shows that only 14 states offer out-of-state physicians a telehealth registration or telemedicine license short of full licensure, exposing a costly compliance gap for digital health startups seeking national scale.

Accuray, Samsung NeuroLogica Partner on CyberKnife Volumetric Imaging

Image
Accuray, Samsung NeuroLogica Partner on CyberKnife Volumetric Imaging

Madison, Wis. – September 27, 2026 -- Accuray Incorporated (NASDAQ: ARAY) has signed agreements with Samsung HME America's NeuroLogica Corp. unit to pursue advanced volumetric imaging capabilities for its CyberKnife System, the companies announced at the ASTRO Annual Meeting in Boston.

Samsung's mobile CT expertise meets Accuray's robotic radiosurgery platform

The collaboration pairs Samsung NeuroLogica's mobile computed tomography and volumetric imaging technology with Accuray's precision treatment delivery, robotic radiosurgery and motion-management systems. No commercial product has been announced; the partnership will proceed through phased technical, clinical and commercial evaluation subject to regulatory requirements.

Leo Cancer Care Launches Pediatric Program After First Upright Proton Treatments

Image
Leo Cancer Care Launches Pediatric Program After First Upright Proton Treatments

Boston – September 27, 2026 -- Leo Cancer Care has confirmed a dedicated pediatric program combining education, distraction and gamification technology, following the world's first pediatric treatments delivered on its upright Marie® positioning and imaging platform.

Stanford Medicine delivers first upright pediatric proton treatments in June 2026

Stanford Medicine treated the initial pediatric patients using the Mevion S250-FIT Proton Therapy System, which integrates Leo Cancer Care's Marie platform and RaySearch Laboratories' RayStation planning software. The early cases demonstrated that upright proton therapy is feasible across a wide pediatric age range, with anesthesia still available when clinically required.

Fuse Oncology to Showcase GE HealthCare iRT-S!GNAL Workflow at ASTRO 2026

Image
Fuse Oncology to Showcase GE HealthCare iRT-S!GNAL Workflow at ASTRO 2026

Boone, N.C. – September 27, 2026 -- Fuse Oncology plans to demonstrate a potential integration linking GE HealthCare's Intelligent Radiation Therapy (iRT) software to its S!GNAL charge capture platform at the ASTRO 2026 Annual Meeting, running September 27-29 in Boston at booth 2533.

Concept links radiation therapy workflow software directly to charge review

The showcased workflow would allow iRT to launch S!GNAL using existing patient information, giving radiation oncology teams a direct path from treatment coordination to targeted charge review without re-entering data across systems. The capability is described as planned for a future iRT release and is currently in development and evaluation, with no confirmed commercial availability date.